These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 22593466)

  • 1. Prognostic factors and clinical outcome of patients with lung adenocarcinoma with carcinomatous meningitis.
    Nakamura Y; Takahashi T; Tsuya A; Naito T; Kenmotsu H; Ono A; Shukuya T; Murakami H; Harada H; Watanabe R; Endo M; Mitsuya K; Nakajima T; Yamamoto N
    Anticancer Res; 2012 May; 32(5):1811-6. PubMed ID: 22593466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response.
    Gow CH; Chien CR; Chang YL; Chiu YH; Kuo SH; Shih JY; Chang YC; Yu CJ; Yang CH; Yang PC
    Clin Cancer Res; 2008 Jan; 14(1):162-8. PubMed ID: 18172267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
    Ruppert AM; Beau-Faller M; Neuville A; Guerin E; Voegeli AC; Mennecier B; Legrain M; Molard A; Jeung MY; Gaub MP; Oudet P; Quoix E
    Eur Respir J; 2009 Feb; 33(2):436-40. PubMed ID: 19181917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure.
    Shukuya T; Takahashi T; Naito T; Kaira R; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Murakami H; Harada H; Mitsuya K; Endo M; Nakasu Y; Takahashi K; Yamamoto N
    Lung Cancer; 2011 Dec; 74(3):457-61. PubMed ID: 21571388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
    Pesek M; Benesova L; Belsanova B; Mukensnabl P; Bruha F; Minarik M
    Anticancer Res; 2009 Jul; 29(7):2767-73. PubMed ID: 19596959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations.
    Yuan S; Yu SL; Chen HY; Hsu YC; Su KY; Chen HW; Chen CY; Yu CJ; Shih JY; Chang YL; Cheng CL; Hsu CP; Hsia JY; Lin CY; Wu G; Liu CH; Wang CD; Yang KC; Chen YW; Lai YL; Hsu CC; Lin TC; Yang TY; Chen KC; Hsu KH; Chen JJ; Chang GC; Li KC; Yang PC
    J Clin Oncol; 2011 Sep; 29(25):3435-42. PubMed ID: 21810691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung.
    Nose N; Sugio K; Oyama T; Nozoe T; Uramoto H; Iwata T; Onitsuka T; Yasumoto K
    J Clin Oncol; 2009 Jan; 27(3):411-7. PubMed ID: 19064969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.
    Kasahara K; Arao T; Sakai K; Matsumoto K; Sakai A; Kimura H; Sone T; Horiike A; Nishio M; Ohira T; Ikeda N; Yamanaka T; Saijo N; Nishio K
    Clin Cancer Res; 2010 Sep; 16(18):4616-24. PubMed ID: 20679350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
    Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
    Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma.
    Lee Y; Shim HS; Park MS; Kim JH; Ha SJ; Kim SH; Cho BC
    Clin Cancer Res; 2012 Mar; 18(6):1760-8. PubMed ID: 22271877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
    Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
    Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
    Nie Q; Yang XN; An SJ; Zhang XC; Yang JJ; Zhong WZ; Liao RQ; Chen ZH; Su J; Xie Z; Wu YL
    Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analysis of the survival rate after radiotherapy in lung cancer patients with bone metastasis: is there an optimal subgroup to be treated with high-dose radiation therapy?
    Komatsu T; Kunieda E; Oizumi Y; Tamai Y; Akiba T
    Neoplasma; 2012; 59(6):650-7. PubMed ID: 22862159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: poorer prognosis associated with T790M-negative status and leptomeningeal metastases.
    Hata A; Katakami N; Yoshioka H; Takeshita J; Tanaka K; Masago K; Fujita S; Kaji R; Imai Y; Monden K; Matsumoto T; Nagata K; Otsuka K; Tachikawa R; Tomii K; Kunimasa K; Iwasaku M; Nishiyama A; Ishida T; Nishimura Y
    Anticancer Res; 2015 Feb; 35(2):1025-31. PubMed ID: 25667490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for carcinomatous meningitis.
    Kanaji N; Bandoh S; Nagamura N; Kushida Y; Haba R; Ishida T
    Intern Med; 2007; 46(19):1651-5. PubMed ID: 17917328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant meningitis secondary to lung adenocarcinoma: an unusual relapse.
    Ano S; Satoh H; Nakazawa K; Ohtsuka M; Anami Y; Noguchi M; Hizawa N
    Intern Med; 2007; 46(20):1749-51. PubMed ID: 17938533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinomatous meningitis and solid tumours.
    Strady C; Ricciarelli A; Nasca S; Liautaud-Roger F; Coninx P
    Oncol Rep; 2000; 7(1):203-7. PubMed ID: 10601619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoplastic Meningitis Due to Lung, Breast, and Melanoma Metastases.
    Le Rhun E; Taillibert S; Chamberlain MC
    Cancer Control; 2017 Jan; 24(1):22-32. PubMed ID: 28178709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Improvement and Prolonged Survival With High Dose Intrathecal Methotrexate for Carcinomatous Meningitis Secondary to a Lung Adenocarcinoma.
    Clatot F; David P; Laberge-Le-Couteulx S; Blot E
    World J Oncol; 2011 Oct; 2(5):262-264. PubMed ID: 29147258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.